PATENT APPLICATION DOCKET NO.: 1767.2011-000

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Khalid K. Sadozai, Tamera B. Gooding, Kyle Bui and Charles H. Sherwood

Application No.: 10/743,557 Group Art Unit: 1614

Filed: December 22, 2003 Examiner: Not yet assigned

·

Confirmation No.: 5063

CROSSLINKED HYALURONIC ACID COMPOSITIONS FOR TISSUE AUGMENTATION

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

[X]

Title:

This Information Disclosure Statement is submitted:

[ ] under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)

.

under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

1	under 37 CFR 1.97(c) together with either:			
	[ ]	a Statement under 37 CFR 1.97(e), as checked below, or		
	[]	a \$180.00 fee under 37 CFR 1.17(p), or		
	(After the	as 27 CER 1 07/h) time nation but before final action or notice of allowance, whichever o		

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

[ ] under 37 CFR 1.97(d) together with:

[ ] a Statement under 37 CFR 1.97(e), as checked below, and

a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

under 37 CFR 1.97(i):
 Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.
 (Filed after payment of issue fee)

Statement Linder 37 CFR 1 07(e)

[ ]

<u> Diateir</u>			<u> </u>		
[]	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or				
[ ]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.				
Statem	ent Un	der 37 (	(Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2	2000	
[]	Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.				
[X]	Enclos	ed here	with is form PTO-1449:		
	[X]	Copie	of the cited references are enclosed.		
		[ ]	Since this application was filed after June 30, 2003, copies of issued U.S. pater and published U.S. applications are not required and are not being provided.	ıts	
	[]	Applic	of the cited references are enclosed except those entered in prior application, U ation No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earli tion contains copies of the cited references.]	.S. er	

submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
 the enclosed English language abstract.

The listed references (AN3, AO3, AP3, AO3 and AU) were cited in the enclosed International Search Report in a counterpart foreign application.

The "concise explanation" requirement (non-English references) for reference(s) [ under 37 CFR 1.98(a)(3) is satisfied by:

the explanation provided on the attached sheet.
the explanation provided in the Specification.
submission of the enclosed International Search Report.

1

[ ]	Applic	cant requests that the following n	on-published pending applic	cations be considered:
Examiner's				
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]
		Examiner	Date	-
	[]	A copy of each above-cited app	lication, including the curre	nt claims, is enclosed.
	[]	A copy of each above-cited app those entered in prior application 35 U.S.C. 120 is claimed.	lication, including the curre on, U.S. Application No. [	nt claims, is enclosed, except ], to which priority under
The E	xaminer nces we	is requested to return a copy of re considered with the next office	the above list of pending appe communication.	plications indicating which
It is re	quested	that the information disclosed h	erein be made of record in th	nis application.
Metho	d of pay	ment:		
[]		ck for the fee noted above is encl panying Reply. A copy of this S		luded in the check with the
[]	Please charge Deposit Account 08-0380 in the amount of $[$ ]. A copy of this Statement is enclosed.			
[X]	Please	charge any deficiency in fees an	d credit any overpayment to	Deposit Account 08-0380.
		R	espectfully submitted,	
		H	IAMILTON, BROOK, SMIT	TH & REYNOLDS, P.C.
		В	Kraig K. Anderson Registration No.: 54,961 Telephone: (978) 341-0036 Facsimile: (978) 341-0136	

PTO-1449 REPRODUCED

SUPPLEMENTAL INFORMATION
DISCLOSURE CITATION
DISCLOSURE CITATION
IN AN APPLICATION
IN AN APPLICATION
Khalid K. Sadozai

PTO-1449 REPRODUCED

APPLICATION
APPLICATION
FIRST NAMED INVENTOR
Khalid K. Sadozai
December

September 23, 2004 EXAMINER
Use several sheets if necessary) Not yet assigned

December 22, 2003

CONFIRMATION NO. GROUP
5063 1614

BADEM	MARKS	FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANS YES	LATION NO	
/C.B./	AN3	WO 02/09792 A1	02/07/2002	Anika Therapeutics, Inc.			
C.B./	AM3	WO 94/02517	02/03/1994	Anika Research, Inc.			
/C.B./	AP3	WO 92/20349	11/26/1992	Genzyme Corporation			
/C.B./	AQ3	EP 0 416 250 A2	03/13/1991	The Research Foundation of State University of New York			

EXAMINER

/Courtney Brown/ (09/24/2007)

DATE CONSIDERED

09/24/2007

				Sheet 2 of
PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 1767.2011-000		LICATION NO. 743,557	
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION  September 23, 2004	FIRST NAMED INVENTOR FILING DATE Khalid K. Sadozai December 2		22, 2003	
	EXAMINER Not yet assigned	5063	RMATION NO.	GROUP 1614

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
/C.B./	AU	Chen, J., et al., "Polysacccharide Hydrogels for Protein Drug Delivery," Carbohydrate Polymers 28 (1995) 69-76.				

EXAMINER		DATE CONSIDERED	
	/Courtney Brown/ (09/24/2007)	09/24/200	7